Enevate Announces 5-Minute Extreme Fast Charge Battery Technology for Electric Vehicles
Enevate Corporation, a lithium-ion (Li-ion) battery technology company, announces HD-Energy® Technology for Electric Vehicles (EVs) which features extreme fast charging in only 5 minutes with high energy density and long driving range that adds up to 240 miles (390 km)—or up to 50 miles (80 km) range with a 60-second charge. This fast charge and very short charging times are better than any other Li-ion technology available today, while meeting automotive requirements for energy density, range, and cost. Enevate licenses its silicon-dominant HD-Energy® Technology to battery and EV automotive manufacturers and suppliers worldwide.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171102005395/en/
Enevate’s extreme fast charge, silicon-dominant Li-ion battery technology allows EV batteries to be charged in 5 minutes, for a driving range of up to 240 miles (390 km). (Graphic: Business Wire)
This new extreme fast charge technology breaks down the barriers to electric vehicle adoption. EVs have been challenged primarily due to their limited range and drivers’ “range anxiety,” long charge times, and high cost. Now, Enevate’s groundbreaking silicon Li-ion battery technology in EV cells (NCM-based) can be charged in 5 minutes at up to a tested 10C charging rate to 75% capacity with uncompromised range and energy densities of over 750 Wh/L, where conventional graphite cells suffer significant degradation with extreme fast charging.
This 5-minute charging allows flow-through charging stations where EV drivers wait just a few minutes to “fill up” just as they would with regular gas stations. In addition, with such short charging times, smaller batteries can be used in some EVs making them much more affordable.
“The benefits of Enevate’s silicon-dominant HD-Energy Technology enable next-generation features that take EVs to the next level,” says Founder & Chief Technology Officer Dr. Benjamin Park. “Extreme fast charges for very short and convenient charging times, higher energy density leading to longer driving ranges, and cold temperature operation with inherent safety advantages make this technology ideal for electric vehicles.”
Enevate’s HD-Energy battery technology can safely charge and discharge down to -40°C and capture more energy during regenerative braking, extending their range in cold climates. A key safety benefit is that Enevate’s HD-Energy Technology is inherently resistant to lithium-plating during fast charge and also during charging in low temperatures, which is a major challenge for conventional graphite Li-ion cells.
Lithium-ion battery pioneer Dr. John Goodenough at University of Texas in Austin agrees, saying “Enevate’s film-based silicon-dominant anode and cell is a truly novel approach and great practical fit for use in EVs addressing the major barriers to EV adoption.”
Enevate Corporation, with global headquarters in California USA, develops and licenses advanced silicon-dominant Li-ion battery technology that revolutionizes the electric vehicle (EV) market by breaking down barriers to EV adoption. Enevate's pioneering work on silicon-dominant anodes and cells has resulted in its breakthrough HD-Energy® Technology featuring extreme fast charging with uncompromised high energy density, excellent low-temperature operation for cold climates, and safety advantages over conventional graphite Li-ion batteries.
Investors include Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, and CEC Capital. Enevate, the Enevate logo, HD-Energy, and eBoost are registered trademarks of the Enevate Corporation. To learn more about or to license Enevate’s industry-defining battery technology, visit www.enevate.com.
On behalf of Enevate
Lynn Lewis, 480.775.8880
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00 | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00 | Tiedote
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26 | Tiedote
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05 | Tiedote
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03 | Tiedote
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 11:00 | Tiedote
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme